Establishment of Primary Xenograft Model From Newly Characterized Patient Extrauterine Carcinosarcoma

Lee, Hyun Joo MS*†; Choi, Hye-Jung MS*; Yang, Heung-Mo PhD*; Kim, You Min BS*; Lee, Jeeyun MD‡§; Chio, Dongil MD§∥; Kim, BoKyung MD, PhD§¶; Choi, Yoon-La MD, PhD§#; Kim, Sung Joo MD, PhD*†§**

International Journal of Gynecological Cancer:
doi: 10.1097/01.IGC.0000434105.98035.c7
Basic Science
Abstract

Background and Objective: The aim of this study was to characterize primary cells from extrauterine carcinosarcoma (CS) and to establish a primary CS xenograft mouse model.

Methods: Primary cells were isolated from a patient with CS and cultured in vitro. Primary CS cells were verified for their ability to consecutively generate tumorigenesis in NOD/SCID mice. The properties of xenograft tumor and explants cells were investigated by immunohistochemistry, cytogenetic, and FACS analysis. Anticancer drug susceptibility of primary CS was analyzed using CCK-8.

Results: Primary CS cells greater than 27 passages in vitro showed an ability of a series of xenograft tumorigenesis in vivo having the same marker expression and cytogenetic character as that of original tumor. In addition, explants of xenograft tumors retained their original characteristics in the in vitro culture system. Finally, the analysis of the susceptibility to anticancer drug revealed that primary CS cells were susceptible to both doxorubicin and nilotinib, which are tyrosine kinase inhibitors.

Conclusions: The primary CS cells and the primary CS xenograft tumorigenesis introduce a new therapeutic model for targeting cancer and also explore a deeper understanding of generation of the tumor itself.

Author Information

*Transplantation Research Center, Samsung Biomedical Research Institute; †Department of Health Sciences & Technology, Graduate School, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University; and ‡Department of Hematological Oncology, §Sarcoma Research Center, and Departments of ∥Radiology, ¶Radiation Oncology, #Pathology, and **Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Address correspondence and reprint requests to Sung Joo Kim, MD, PhD, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-Dong, Gangnam-Gu, Seoul, 135-710, Republic of Korea. E-mail: kmhyj.kim@samsung.com, kmhyj111@hotmail.com; or Yoon-La Choi, MD, PhD, Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-Dong, Gangnam-Gu, Seoul, 135-710, Republic of Korea. E-mail: yla.choi@samsung.com.

H.J.L. and H.-J.C. contributed equally to this work.

This work was supported by grants from the Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs (A092255), Republic of Korea.

The authors declare no conflicts of interest.

Received April 4, 2013

Accepted August 7, 2013

© 2013 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.